Another breakthrough for team studying our solar system’s protective bubble
Peer-Reviewed Publication
A multi-institutional team of astrophysicists headquartered at Boston University, led by BU astrophysicist Merav Opher, has made a breakthrough discovery in our understanding of the cosmic forces that shape the heliosphere.
Our understanding of how microscopic structure and changes in the shape of food affect food texture remains underdeveloped, so researchers from Denmark and Germany conducted a series of experiments relating food microstructure and rheology to texture. In Physics of Fluids, they used coherent anti-Stokes Raman scattering microscopy to relate the molecular makeup of the fat in foods with the rheological and mechanical properties of the food. The foods in question: foie gras and pâté.
Scientists at La Jolla Institute for Immunology (LJI) and Massachusetts Institute of Technology (MIT), have found a possible way to improve the effectiveness of COVID-19 vaccines—and any vaccine.
Researchers designed a new nanoparticle adjuvant that may be more potent than others now in use. Studies in mice showed it significantly improved antibody production following vaccination against HIV, diphtheria and influenza.
Three-dimensional fault models are generally more accurate than two-dimensional line models at sending ground shaking alerts to the correct areas as part of an earthquake early warning system, according to a new study.
Air trapped with ice below glacier surfaces becomes a compressed bubble-ice mixture that builds pressure during the long passage to the glacier terminus. The glacier ice holds ancient bubbles of air that can be up to 20 atmospheres of pressure and generate detectable sounds when they are released as the ice melts. Scientists can listen to the release of the air and potentially use the sounds to help them gauge the impact of climate change on the ice floes.
What The Study Did: This study found that Medicare spending from 2015 through 2019 on drugs with an accelerated approval indication doubled from $4.7 billion to $9.1 billion, with most of this growth among Part B drugs.